Company intelligence / Profile preview

Unlimited Bio

Ownership: Private
Development stage: Preclinical

Overview

Unlimited Bio is one of two companies that administer genetic therapies in Prospera, focusing on translating cutting-edge science into real-world longevity solutions[1]

Therapeutic areas: Other
Modalities: Genetic therapies
Industry: Biotech

Drug pipeline

1 asset

VEGF plasmid

Pre-clinical

Indications: Hair loss, Muscle enhancement, Peripheral arterial disease, Diabetic foot ulcers

Beyond the preview

Go deeper on Unlimited Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unlimited Bio.

Explore the full profile